Verapamil plus captopril in moderate-severe hypertensive patients

被引:0
作者
MoraMacia, J
Ocon, J
Garrido, J
Velasco, J
Barcelo, P
机构
来源
NEFROLOGIA | 1996年 / 16卷 / 01期
关键词
verapamil; captopril; moderate-severe hypertension;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objetive: We evaluated with 24 hour ambulatory blood pressure monitoring (ABMP) throughout 24 hours the combination of long acting verapamil once a day plus captopril twice a day (V + C) in moderately-severely hypertensive patients. We also compared choice of dosage between office blood pressure (OBP) and ABMP using this combination therapy. Design and methods: In 21 hypertensive patients who did not respond previously to monotherapy -aged 37-67 y.o., 13 males and 8 females- we meassured OBP and 24-hour-ABPM alter a washout period (PO) and at 4 (PA), 8 (PB) and 12 weeks (PC) with a combination oi V + C. The dossage was: V + C, 240 + 50 mg during PA, ii diastolic OBP was > 89 mmHg it was increased to 360 + 50 mg at PB, and to V + C 360 + 100 mg at PC. Results: OBP al PO in mmHg were: 172 +/- 16/120 +/- 11; at PA 149 +/- 19/102 +/- 9; al PB 144 +/- 24/98 +/- 11, and al PC 142 +/- 23/97 +/- 9, (p < 0.01, ANOVA). Diurnal ABP in mmHg al PO were: 159 +/- 19/107 +/- 11 at PA 141 +/- 23/94 +/- 11, at PB 140 +/- 21/89 +/- 11, and at PC 139 +/- 20/89 +/- 11, (p < 0.01, ANOVA). The number oi patients controlled according to OBP and ABP were at PA: 1/7, at PB: 3/11 and PC: 5/8. Chi square test was significant only when comparing OBP and ABP al PA and PB (p < 0.05). Conclusion: We observed the most important decrease in blood pressure between periods with the initial dosage oi the combination V + C (240 + 50 mg) at PA. However, ABPM showed the best efficacy oi V + C at PB (360 +/- 50 mg). Increasing dosage did not achieved better control oi blood pressure. On the contrary according to the office blood pressure we increased dossage in every period. Thus there is a difference between office blood pressure and diurnal blood pressure monitoring which makes selection of patients and decision of final results different with each method used.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 31 条
  • [11] MANAGEMENT OF HYPERTENSION - POTENTIAL TRADE-OFFS ON CORONARY RISK
    GRIMM, RH
    FLACK, JM
    [J]. AMERICAN JOURNAL OF MEDICINE, 1989, 87 (2A) : S62 - S65
  • [12] CALCIUM-CHANNEL BLOCKADE WITH NIFEDIPINE AND ANGIOTENSIN CONVERTING-ENZYME INHIBITION WITH CAPTOPRIL IN THE THERAPY OF PATIENTS WITH SEVERE PRIMARY HYPERTENSION
    GUAZZI, MD
    DECESARE, N
    GALLI, C
    SALVIONI, A
    TRAMONTANA, C
    TAMBORINI, G
    BARTORELLI, A
    [J]. CIRCULATION, 1984, 70 (02) : 279 - 284
  • [13] JABARY NS, 1994, NEFROLOGIA, V14, P297
  • [14] ADDITIVE EFFECTS OF VERAPAMIL AND ENALAPRIL IN THE TREATMENT OF MILD-TO-MODERATE HYPERTENSION
    LEVINE, JH
    FERDINAND, KC
    CARGO, P
    LAINE, H
    LEFKOWITZ, M
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1995, 8 (05) : 494 - 499
  • [15] LURBE E, 1991, NEFROLOGIA, V11, P144
  • [16] MACIA JM, 1991, MED CLIN-BARCELONA, V97, P292
  • [17] MACIA JM, 1991, HIPERTENSION, V8, P137
  • [18] MORA J, 1989, NEFROLOGIA, V9, P123
  • [19] MORA J, 1992, HIPERTENSION, V9, P1
  • [20] MORAMACIA J, 1993, MED CLIN-BARCELONA, V101, P450